Loading...
XKRX
099430
Market cap149mUSD
Jul 10, Last price  
4,000.00KRW
1D
2.96%
1Q
-23.95%
IPO
-49.61%
Name

BioPlus Co Ltd

Chart & Performance

D1W1MN
XKRX:099430 chart
P/E
15.45
P/S
2.55
EPS
258.95
Div Yield, %
1.29%
Shrs. gr., 5y
3.66%
Rev. gr., 5y
30.12%
Revenues
90.90b
+36.87%
17,020,655,77024,366,600,86037,418,198,00056,718,819,00065,042,901,00066,409,595,00090,896,013,000
Net income
15.00b
+6.01%
5,623,358,7009,703,010,83010,724,704,00021,136,873,00025,580,547,00014,151,120,00015,001,439,000
CFO
17.65b
-20.80%
4,963,611,42010,043,212,00013,352,359,87013,359,309,00020,289,093,00022,290,032,00017,654,683,000
Dividend
Dec 29, 202550 KRW/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Based in Seongnam-si, South Korea, Bio Plus Co., Ltd, established in 2003, is dedicated to the investigation, formulation, production, and commercialization of bio-based items. The company’s diverse offerings include a variety of dermal fillers, such as SkinPlus – Hyal, Bio+ Dew, HyalDew, DeneB Classic, Stilea, and 3-Senses. Additionally, Bio Plus manufactures critical medical products: InterBlock, an absorbable anti-adhesion barrier; Synofil, utilized for synovial fluid replacement; and Blad-Care, a treatment for temporary alleviation of cystitis discomfort. Its mesotherapy portfolio features Kiara Reju for skin revitalization, Slim Slimmer for lipolysis, LumiDew for skin brightening, and JuveniHill for addressing wrinkles. The firm also supplies hair and scalp wellness products under the BelloHa and BellaChe names. Rounding out its extensive catalog are La Bella brand cosmetics, which include heparinoid essence, EGF balls, and specialized skin care gels.
IPO date
Sep 27, 2021
Employees
Domiciled in
KR
Incorporated in
KR

Valuation

Title
KRW in thousands, except ratios and share amounts
FYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT